Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totaling 125,511 shares, an increase of 169.5% from the April 15th total of 46,578 shares. Based on an average trading volume of 131,384 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DWTX. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Monday, April 27th. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dogwood Therapeutics presently has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is currently owned by hedge funds and other institutional investors.

Dogwood Therapeutics Stock Down 7.6%

Dogwood Therapeutics stock opened at $1.83 on Friday. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The firm has a 50 day moving average price of $2.09 and a 200-day moving average price of $3.64. The company has a market capitalization of $61.12 million, a P/E ratio of -0.17 and a beta of 1.68.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Equities analysts expect that Dogwood Therapeutics will post -0.93 EPS for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.